R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study | Semantic Scholar (2024)

This review systematically collates and discusses the outcomes associated with the use of immunochemotherapy in older patients with DLBCL, as well as considering the impact of full-dose immunochemotherapy on quality of life in older and frail patients and presenting recommendations for selecting patients likely to benefit from reduced dosing.

This was a prospective, multicenter, single-arm, phase 2 study of patients aged ≥75yrs with newly diagnosed DLBCL and demonstrated the deliverability of ibrutinib with R-mini-CHOP with a median average relative total dose of 97.

The addition of lenalidomide to R-miniCHOP does not improve OS and an attenuated dose of rituximab delivered subcutaneously was safe in this population of elderly patients.

The study shows promising activity and manageable toxicity profile of BR combination as first-line therapy for patients with DLBCL who are prospectively defined as frail according to a simplified CGA, as adopted in this trial.

The 3-year OS is similar for patients treated with CHOP in combination with R-originator or R-biosimilars and, therefore, favors the use of R- biosimilar in DLBCL treatment management.

Early clinical data with Mosun as 1L therapy for elderly/unfit pts with 1L DLBCL who are unable to tolerate full-dose CIT is presented, with promising efficacy and tolerable safety shown.

The study did not meet its primary end point in the intent-to-treat (ITT) population and the activated B-cell (ABC) DLBCL subgroup, but in patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS, PFS, and OS with manageable safety.

Among patients with previously untreated intermediate-risk or high-risk DLBCL, the risk of disease progression, relapse, or death was lower among those who received pola-R-CHP than among those Who received R-CHOP, and the safety profile was similar in the two groups.

It is shown that the NHS urgent cancer pathway is associated with a superior survival after adjusting for multiple confounders, and equivalent survival for R-CHOP and R-miniCHOP was demonstrated in those ≥80 years.

...

...